12 September 2024NewsCareersMuireann Bolger

WBD to merge with firm to create ‘powerhouse’ practice

Deal marks the third major M&A to be announced so far this month | Combined firms have a total gross revenue of more than $742 million | Business marriage seen as “natural fit and clear win-win”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Careers

WilmerHale trade secrets expert moves to new firm

7 July 2026 Focusing on technology and life sciences clients, the new San Fran-based Debevoise & Plimpton hire brings both in-house and private practice litigation experience across trade secrets and commercial disputes.

Careers

HGF expands European offering with pair of in-house hires

2 July 2026 The firm has appointed two new partners in Basel and Bristol, adding decades of expertise from the pharmaceutical and biotech sectors to its growing life sciences practice.

Careers

Vinson & Elkins grows West Coast patent and trade secrets bench

1 July 2026 A first-chair trial lawyer with two decades in high-stakes patent and trade secret disputes brings experience across medical devices, biologics, and pharmaceuticals, alongside a broader technology-focused practice.

More features

WilmerHale trade secrets expert moves to new firm

UPC revives patent, but timing sinks Guardant’s appeal

China’s medtech shake-up forces rethink on pricing, IP and innovation

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

Vinson & Elkins grows West Coast patent and trade secrets bench

Will Mounjaro and Zepbound get their first US generic rival?

WBD to merge with firm to create ‘powerhouse’ practice

More on this story

Editor's picks

Editor's picks

More features